Business Context and Reporting Period
Adlai Nortye Ltd. (NASDAQ: ANL) is a clinical-stage biopharmaceutical company focused on developing next-generation cancer immunotherapies and RAS-targeting therapies. This Form 6-K, filed on December 29, 2025, reports unaudited financial results and operational highlights for the six-month period ended June 30, 2025.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $18.3 million | $27.7 million |
| Research & Development Expenses | $15.2 million | $26.0 million |
| General & Administrative Expenses | $4.1 million | $4.7 million |
| Net Cash Used in Operating Activities | $15.1 million | $28.4 million |
| Cash and Cash Equivalents (End of Period) | $44.1 million | $98.0 million |
| Restricted Cash (End of Period) | $18.2 million | $0 |
| Interest-Bearing Bank Borrowings | $44.1 million | $26.3 million |
| Total Shareholders' Equity | $7.9 million | $25.5 million |
Material Changes vs. Prior Period
- Reduced Net Loss: Net loss decreased by 33.6% to $18.3 million, driven primarily by a 41.4% reduction in R&D expenses and a 13.8% decrease in G&A expenses.
- Expense Reductions: R&D spending dropped to $15.2 million as current projects remain in early stages with lower service fees. G&A declined due to reduced share-based compensation expenses.
- Other Gains: Other gains decreased by 45% to $1.4 million, attributed to a reduction in government grants received.
- Liquidity Position: Cash and cash equivalents declined from $60.9 million to $44.1 million. However, restricted cash increased from nil to $18.2 million. Total interest-bearing borrowings increased significantly from $26.3 million to $44.1 million.
- Equity Erosion: Total shareholders' equity decreased from $25.5 million to $7.9 million due to the period's net loss.
Guidance, Outlook, and Operational Progress
Management provided updates on the clinical pipeline with no specific financial guidance provided in this filing.
- AN8025: Phase I clinical study is ongoing. This tri-specific antibody fusion protein targets PD-L1, CD86, and LAG3.
- AN9025: An oral pan-RAS(ON) inhibitor. The Company expects to initiate the Phase I clinical study in Q1 2026.
- AN4035: A CEACAM5-targeting ADC. The Company expects to submit the Investigational New Drug (IND) application in mid-2026.
- AN4005: An oral PD-L1 inhibitor. The trial has advanced to the Expansion Phase. Proof-of-concept data is expected in 2026.
- AN0025: An EP4 antagonist. The ARTEMIS Phase II study in rectum cancer is ongoing, with futility analysis results expected in Q1 2026.
Risks: The filing includes standard forward-looking statement disclaimers regarding clinical trial timing, regulatory approvals, capital requirements, and the ability to access additional financing.
Investor Verification Checklist
- Verify the sustainability of the reduced burn rate given the increase in interest-bearing borrowings to $44.1 million.
- Confirm the timeline for the initiation of the AN9025 Phase I trial (expected Q1 2026) and the AN4035 IND submission (expected mid-2026).
- Assess the impact of the $18.2 million in restricted cash on overall liquidity and operational flexibility.
- Monitor the upcoming futility analysis for the AN0025 ARTEMIS Phase II study in Q1 2026.
- Review the company's capital raise plans, as total equity has dropped to $7.9 million while operating cash burn continues.